<DOC>
	<DOC>NCT00949975</DOC>
	<brief_summary>The primary objective is to evaluate the dose-response relationship and efficacy of AZD9668 at 3 dose levels compared with placebo in symptomatic COPD patients by assessing effects on lung function and symptoms of COPD.</brief_summary>
	<brief_title>A Dose Range Finding Study to Evaluate the Efficacy and Safety of AZD9668 Administered Orally at Three Dose Levels to Patients With Chronic Obstructive Pulmonary Disease (COPD) on Treatment With Tiotropium</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>Diagnosis of COPD with symptoms over 1 year Smokers or exsmokers Males or postmenopausal females between 40 and 80 years old Able to use electronic devices Past history or current evidence of clinically significant heart disease Current diagnosis of asthma Patients who require long term oxygen therapy Treatment with antibiotics within 4 weeks of study visit 1b</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Chronic</keyword>
	<keyword>Obstructive</keyword>
	<keyword>Pulmonary</keyword>
	<keyword>Lung</keyword>
	<keyword>Respiratory disease</keyword>
	<keyword>Efficacy</keyword>
	<keyword>Safety and tolerability</keyword>
	<keyword>Placebo-controlled</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>COPD</keyword>
</DOC>